Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

5(50%)

Results Posted

0%(0 trials)

Terminated

1(10%)

Phase Distribution

Ph phase_3

10%

Ph early_phase_1

10%

Ph phase_2

30%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Early Phase 1First-in-human

1(10.0%)

Phase 1Safety & dosage

5(50.0%)

Phase 2Efficacy & side effects

3(30.0%)

Phase 3Large-scale testing

1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(4)

Terminated(1)

Detailed Status

Recruiting5

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (10.0%)

Phase 15 (50.0%)

Phase 23 (30.0%)

Phase 31 (10.0%)

Trials by Status

recruiting550%

completed440%

terminated110%

Recent Activity

5 active trials

Showing 5 of 10

recruitingphase_3

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500

recruitingphase_2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825

recruitingphase_1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

NCT06364410

terminatedphase_1

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

NCT06351332

completedphase_2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

NCT04814108

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07546500Phase 3

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Recruiting

NCT05128825Phase 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting

NCT06364410Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Recruiting

NCT06351332Phase 1

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Terminated

NCT04814108Phase 2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Completed

NCT04833582Phase 1

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed

NCT04158336Phase 1

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors